News: CARA Leading Product Passes Test $CARA

Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced statistically significant topline results from its Phase 2 trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus (UP). Uremic pruritus is a chronic …

News: CARA Leading Product Passes Test $CARA Read More »